SOURCE: Rheologics Technologies, Inc.

February 05, 2007 15:17 ET

Rheologics Acquires Cardiodyne Electronics

EXTON, PA -- (MARKET WIRE) -- February 5, 2007 -- Rheologics Technologies, Inc., ("Rheologics" or the "Company"), (PINKSHEETS: RTGI), the leader in the study of blood viscosity and its relationship to cardiovascular disease, announced today the acquisition of Cardiodyne Electronics, Inc., a basic research firm in the biomedical field. As part of the transaction, Rheologics acquired the following technologies: finger-stick blood viscometer, blood volume analyzer, and two blood filtration technologies in the apheresis class.

Rheologics Chief Scientific Officer Kenneth R. Kensey, MD, said, "The acquisition of these technologies is to strengthen our pipeline. We are undertaking the burden to educate the physician and consumer markets on the importance of whole blood viscosity and its relationship to cardiovascular risk. As we invest in this education process, we will continue to develop and acquire systems that may boost our portfolio and enable us to maintain a leadership position in this field long-term."

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information